Cambridge Investment Research Advisors’s Beam Therapeutics BEAM Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,123	Closed	-$198K	–	3628
2025 Q1	$198K	Sell	10,123 -455	-4%	-$11.9K	﹤0.01%	3215
2024 Q4	$262K	Buy	10,578 +143	+1%	+$3.65K	﹤0.01%	2950
2024 Q3	$256K	Buy	+10,435	New	+$270K	﹤0.01%	2946
2023 Q1	–	Sell	-5,658	Closed	-$221K	–	3162
2022 Q4	$221K	Buy	5,658 +197	+4%	+$8.82K	﹤0.01%	2669
2022 Q3	$260K	Buy	+5,461	New	+$312K	﹤0.01%	2484
2022 Q1	–	Sell	-2,616	Closed	-$208K	–	3168
2021 Q4	$208K	Sell	2,616 -867	-25%	-$74.2K	﹤0.01%	2861
2021 Q3	$303K	Sell	3,483 -4,136	-54%	-$416K	﹤0.01%	2458
2021 Q2	$981K	Buy	7,619 +4,306	+130%	+$343K	﹤0.01%	1548
2021 Q1	$265K	Sell	3,313 -513	-13%	-$48.8K	﹤0.01%	2373
2020 Q4	$312K	Buy	+3,826	New	+$188K	﹤0.01%	2101

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Cambridge Investment Research Advisors's BEAM Position: Q2 2025 in Review

Cambridge Investment Research Advisors sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 10,123 shares — an estimated $198K sold.

Cambridge Investment Research Advisors first reported a position in BEAM in Q4 2020 and held it in 10 quarters. The position peaked at $981K in Q2 2021. 216 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

Cambridge Investment Research Advisors reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
Cambridge Investment Research Advisors sold 10,123 Beam Therapeutics shares in Q2 2025, an estimated $198K.
Cambridge Investment Research Advisors first reported a position in Beam Therapeutics in Q4 2020 and held it in 10 quarters.
Cambridge Investment Research Advisors's Beam Therapeutics position peaked at $981K in Q2 2021.
216 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.